The Centers for Medicare and Medicaid Services (CMS) is hoping to encourage greater use of innovative contracting models in a recently-proposed package of changes to Medicaid.
Washington University in St. Louis associate law professor Rachel Sachs in a recent Health Affairs blog post writes that while the changes wouldn’t have a major impact on drug pricing, “it is a thoughtful tweak to existing regulations that would help mitigate uncertainty for pharmaceutical companies interested in entering into these agreements.”
In her post, Sachs outlines what the reforms aim to address, as well as how it aligns with the Trump administration’s drug pricing efforts.
According to a Pink Sheet analysis, some experts are concerned about the impact on drug prices if the proposal gets the green light.
To read the blog post, click here.
To read the Pink Sheet report, click here.
